Please login to the form below

Not currently logged in
Email:
Password:

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Those are headed by Mayzent (siponimod) – due to launch in the first quarter of 2019 – which it says is the “first and only drug proven to delay progression” in patients with

Latest news

  • Novartis files for approval of MS drug in EU, US Novartis files for approval of MS drug in EU, US

    Siponimod also seemed to have a meaningful benefit on patients’ cognitive processing speed in the study. ... Siponimod has an opportunity to tap into a niche not fully addressed by rival therapies.

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    Orally-active siponimod reduces risk of disability progression.  . A follow-up to Novartis' multiple sclerosis therapy Gilenya has been shown to work in a tough-to-treat form of multiple sclerosis ... MS). The new drug candidate - called siponimod

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Tackling a formidable foe Tackling a formidable foe

    Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics